Acamprosate Calcium, Delayed-Release Tablets, 333 mg, 180 tablets bottles, Rx only, Mylan Pharmaceuticals Inc., Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 266505, NDC 0378-6333-80.
Published August 26, 2026 · Recall initiated: July 24, 2026
Summary
FDA records drug Class II recall D-0774-2026, published August 26, 2026 and initiated July 24, 2026. Recalling firm: Mylan Pharmaceuticals Inc; Status: Ongoing; Lot: Lot# 3227809; Expiry:10/2026; NDC #: 0378-6333-80. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Dissolution Specifications
What to do
Voluntary: Firm initiated · Letter
Get an email if ACAMPROSATE CALCIUM has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- ACAMPROSATE CALCIUM
- Manufacturer
- Mylan Pharmaceuticals Inc
- Distributor
- US Nationwide.
- UPC
- 0303786333806
- Lot
- Lot# 3227809; Expiry:10/2026; NDC #: 0378-6333-80
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDACarbamazepine Tablets, USP, 200mg, packaged in a)1000-count bottles (NDC 51407-215-10), b) 100-count bottlesAugust 26, 2026
- FDAMorphine Sulfate Injection, USP, 2 mg /mL, 1 mL single-dose Simplist prefilled syringes, For Intramuscular orAugust 26, 2026
- FDACarbamazepine Tablets, USP, 200mg, 1000 count bottles, Rx only, Manufactured by: Taro PharmaceuticalAugust 26, 2026
- FDANitroglycerin injection, USP, 50 mg/10 mL (5 mg/mL), packaged in a) 10 mL vials (NDC 0517-4810-01), b) 25x10mLAugust 26, 2026
- FDALibtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution,August 26, 2026
- FDACyanocobalamin injection USP, 1,000 mcg/mL, For IM or SC Use Only, packaged in a) 1 mL Multi-Dose Vial (NDCAugust 26, 2026
Questions about this recall
Was Acamprosate Calcium, Delayed-Release Tablets, 333 mg, 180 tablets bottles, Rx only, Mylan Pharmaceuticals Inc., Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 266505, NDC 0378-6333-80. recalled?
Yes. FDA published recall D-0774-2026 on August 26, 2026. Reported hazard: Failed Dissolution Specifications
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: ACAMPROSATE CALCIUM. UPC: 0303786333806.